Suppression of eEF2 phosphorylation alleviates synaptic failure and cognitive deficits in mouse models of Down syndrome
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.13916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Xin Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Down Syndrome, Disease Models, Animal, Elongation Factor 2 Kinase, Cognitive Dysfunction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
INTRODUCTION Cognitive impairment is a core feature of Down syndrome (DS), and the underlying neurobiological mechanisms remain unclear. Translation dysregulation is linked to multiple neurological disorders characterized by cognitive impairments. Phosphorylation of the translational factor eukaryotic elongation factor 2 (eEF2) by its kinase eEF2K results in inhibition of general protein synthesis. METHODS We used genetic and pharmacological methods to suppress eEF2K in two lines of DS mouse models. We further applied multiple approaches to evaluate the effects of eEF2K inhibition on DS pathophysiology. RESULTS We found that eEF2K signaling was overactive in the brain of patients with DS and DS mouse models. Inhibition of eEF2 phosphorylation through suppression of eEF2K in DS model mice improved multiple aspects of DS‐associated pathophysiology including de novo protein synthesis deficiency, synaptic morphological defects, long‐term synaptic plasticity failure, and cognitive impairments. DISCUSSION Our data suggested that eEF2K signaling dysregulation mediates DS‐associated synaptic and cognitive impairments. Highlights Phosphorylation of the translational factor eukaryotic elongation factor 2 (eEF2) is increased in the Down syndrome (DS) brain. Suppression of the eEF2 kinase (eEF2K) alleviates cognitive deficits in DS models. Suppression of eEF2K improves synaptic dysregulation in DS models. Cognitive and synaptic impairments in DS models are rescued by eEF2K inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
- Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
- Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
ORCID-Profile: Tao Ma
Förderung
- NIA NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Wang, X., Yang, Q., Zhou, X., Keene, C. D., Ryazanov, A. G., & Ma, T. (2024). Suppression of eEF2 phosphorylation alleviates synaptic failure and cognitive deficits in mouse models of Down syndrome. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13916
Vancouver
Wang X, Yang Q, Zhou X, Keene CD, Ryazanov AG, Ma T. Suppression of eEF2 phosphorylation alleviates synaptic failure and cognitive deficits in mouse models of Down syndrome. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13916
BibTeX
@article{Wang2024,
author = {Wang, Xin and Yang, Qian and Zhou, Xueyan and Keene, C Dirk and Ryazanov, Alexey G and Ma, Tao},
title = {Suppression of eEF2 phosphorylation alleviates synaptic failure and cognitive deficits in mouse models of Down syndrome},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.13916}
}
EUVIMED